The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study

Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic conditions but remains substantially underdiagnosed. The aim of our study was to investigate the prevalence of HeFH in the population of 11 different regions of Russia. Individuals were selected from the Epidemiology...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2021-05, Vol.11 (6), p.464
Main Authors: Meshkov, Alexey N, Ershova, Alexandra I, Kiseleva, Anna V, Shalnova, Svetlana A, Drapkina, Oxana M, Boytsov, Sergey A, On Behalf Of The Fh-Esse-Rf Investigators
Format: Article
Language:English
Subjects:
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Coronary artery
Epidemiology
Family medical history
Genetic screening
Genomics
Heart diseases
Hypercholesterolemia
Lipids
Low density lipoprotein
Population
Precision medicine
Risk factors
Software
Statins
Statistical analysis
Xanthoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic conditions but remains substantially underdiagnosed. The aim of our study was to investigate the prevalence of HeFH in the population of 11 different regions of Russia. Individuals were selected from the Epidemiology of Cardiovascular Risk Factors and Diseases in Regions of the Russian Federation Study. All participants who had low-density lipoprotein cholesterol (LDL-C) higher than 4.9 mmol/L, or LDL-C lower than 4.9 mmol/L, but had statin therapy, were additionally examined by FH experts. FH was diagnosed using the Dutch Lipid Clinic Network criteria, incorporating genetic testing. HeFH prevalence was assessed for 18,142 participants. The prevalence of patients with definite or probable HeFH combined was 0.58% (1 in 173). A total of 16.1% of patients with definite or probable HeFH had tendon xanthomas; 36.2% had mutations in one of the three genes; 45.6% of FH patients had coronary artery disease; 63% of HeFH patients received statins; one patient received an additional PCSK9 inhibitor; no patients received ezetimibe. Only 3% of patients reached the LDL-C goal based on 2019 ESC/EAS guidelines. Underdiagnosis and undertreatment of FH in Russia underline the need for the intensification of FH detection with early and aggressive cholesterol-lowering treatment.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm11060464